GHP Investment Advisors Inc. Has $45,000 Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

GHP Investment Advisors Inc. reduced its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 57.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 429 shares of the medical equipment provider’s stock after selling 572 shares during the period. GHP Investment Advisors Inc.’s holdings in Zimmer Biomet were worth $45,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Choreo LLC increased its position in shares of Zimmer Biomet by 5.0% in the 4th quarter. Choreo LLC now owns 15,235 shares of the medical equipment provider’s stock valued at $1,607,000 after buying an additional 729 shares in the last quarter. Tectonic Advisors LLC grew its stake in Zimmer Biomet by 21.7% in the fourth quarter. Tectonic Advisors LLC now owns 4,439 shares of the medical equipment provider’s stock valued at $469,000 after acquiring an additional 792 shares during the period. Money Concepts Capital Corp increased its holdings in shares of Zimmer Biomet by 5.9% in the fourth quarter. Money Concepts Capital Corp now owns 3,538 shares of the medical equipment provider’s stock worth $374,000 after acquiring an additional 196 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Zimmer Biomet by 26.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,156 shares of the medical equipment provider’s stock worth $2,361,000 after purchasing an additional 4,645 shares during the period. Finally, E. Ohman J or Asset Management AB grew its position in shares of Zimmer Biomet by 14.0% in the 4th quarter. E. Ohman J or Asset Management AB now owns 10,150 shares of the medical equipment provider’s stock valued at $1,072,000 after purchasing an additional 1,250 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analysts Set New Price Targets

ZBH has been the topic of several research analyst reports. JMP Securities restated a “market outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a report on Friday. Oppenheimer cut their price objective on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 15th. Barclays lowered their target price on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a report on Thursday, December 12th. Raymond James cut their price target on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday. Finally, JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $124.70.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $101.01 on Friday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $99.93 and a fifty-two week high of $133.90. The company has a market cap of $20.11 billion, a price-to-earnings ratio of 19.20, a PEG ratio of 1.88 and a beta of 1.02. The stock has a fifty day moving average price of $107.56 and a 200-day moving average price of $108.16.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. During the same quarter in the prior year, the company earned $2.20 earnings per share. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.95%. The ex-dividend date of this dividend was Monday, December 30th. Zimmer Biomet’s dividend payout ratio is presently 18.25%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.